Radioactive drug trial offers hope for advanced melanoma patients
NCT ID NCT07076550
Summary
This early-stage trial is testing a new radioactive drug for adults with advanced melanoma that has spread or cannot be removed by surgery. The main goals are to find the safest dose and see if the drug can shrink tumors. Participants receive the drug once every six weeks for up to six treatments and have regular checkups to monitor their health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Austin Health
RECRUITINGMelbourne, Victoria, 3084, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fiona Stanley Hospital
NOT_YET_RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
GenesisCare Murdoch
NOT_YET_RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.